Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Verrica Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
VRCA
Nasdaq
2834
https://verrica.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
- May 15th, 2024 11:30 am
Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
- May 14th, 2024 7:01 am
Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review
- May 13th, 2024 1:12 pm
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
- May 13th, 2024 12:40 pm
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
- May 13th, 2024 11:30 am
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
- May 9th, 2024 11:30 am
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
- May 8th, 2024 11:30 am
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
- May 6th, 2024 10:35 am
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?
- Apr 25th, 2024 9:48 am
Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss
- Apr 3rd, 2024 11:36 am
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- Apr 2nd, 2024 11:30 am
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
- Mar 26th, 2024 11:30 am
When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?
- Mar 2nd, 2024 12:18 pm
Verrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
- Mar 2nd, 2024 12:18 pm
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript
- Mar 1st, 2024 2:10 pm
Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results
- Feb 29th, 2024 1:11 pm
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
- Feb 29th, 2024 12:30 pm
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
- Feb 27th, 2024 12:30 pm
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
- Feb 22nd, 2024 12:30 pm
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
- Feb 5th, 2024 12:30 pm
Scroll